Diuretics are substances that increase production of urine.
Most diuretics act to increase excretion of sodium, which is followed by water.
Because increased urine production results in reduced blood volume, diuretics are commonly
used to treat primary hypertension and edema.
Changes in body fluid and electrolytes induced by diuretics can also be therapeutic for some
other conditions.
Sodium and water are filtered in the glomerular capsule of nephrons, then reabsorbed back
to the blood at various sites along the renal tubule.
Different classes of diuretics prevent sodium reabsorption, and thus increase sodium loss,
at different sites, by different mechanisms.
Carbonic anhydrase inhibitors inhibit the enzyme carbonic anhydrase, which is required
for reabsorption of bicarbonate in the proximal tubule.
This leads to greater sodium loss, in the form of sodium bicarbonate, and subsequently
greater water loss in the urine.
These inhibitors have the weakest diuretic effect because most of sodium lost at this
early stage is reclaimed further down the renal tubule.
Increased delivery of sodium to the collecting duct increases its reabsorption at this site
through epithelial sodium channels, in exchange for a greater potassium loss, and may cause
hypokalemia.
Loss of bicarbonate also affects acid-base balance, producing metabolic acidosis.
Carbonic anhydrase inhibitors are rarely prescribed for cardiovascular diseases; they are mainly
used in the treatment of glaucoma.
Osmotic diuretics, such as mannitol, promote water loss directly through osmosis.
Being filtered without subsequent reabsorption, mannitol stays in the renal tubule, creating
a higher osmolality which attracts water by osmosis.
It produces a greater loss of water compared to sodium and potassium.
Mannitol is not usually used to treat edema because its initial presence in the circulation
may actually further increase fluid volume to a dangerous level.
It is however effective in lowering intracranial pressure in patients with head injury, as
well as lowering intraocular pressure in acute glaucoma.
Osmotic diuretics act on the entire renal tubule, with predominant effect on the proximal
tubule and the descending loop of Henle.
Loop diuretics inhibit the sodium/potassium/chloride cotransporter in the thick ascending limb
of the loop of Henle.
These are very powerful diuretics because this transporter not only reabsorbs a large
share of sodium, but is also responsible for the osmolarity gradient in the medulla that
enables the collecting duct to concentrate urine.
As the loop diuretics cause the salinity gradient to diminish, the collecting duct loses less
water, more water is excreted in urine.
Because the sodium/potassium/chloride cotransporter acts in conjunction with back diffusion of
potassium to create a positive lumen potential that drives reabsorption of other positive
ions, its inhibition by loop diuretics also induces a greater loss of these ions.
Side effects include electrolyte imbalances, metabolic alkalosis, hypovolemia due to excessive
loss of water, loss of hearing due to inhibition of a similar transporter in the inner ear,
and gout due to interference with transporters involved in urate secretion.
Thiazide diuretics inhibit the sodium/chloride cotransporter in the distal tubule, which
reabsorbs about 5% of the sodium load, and are not as powerful as loop diuretics.
However, thiazides also have a vasodilation effect by a still poorly understood mechanism.
Thiazides are first-line drugs for uncomplicated hypertension and most effective for heart
failure prevention.
Unlike loop diuretics, thiazides reduce calcium loss in urine and can be used to prevent formation
of new calcium kidney stones.
This is because lower intracellular sodium induced by thiazides leads to higher calcium
reabsorption mediated by sodium/calcium exchanger located on the basolateral membrane.
Other side effects are similar to those of loop diuretics and include hypokalemia, metabolic
alkalosis and hyperuricemia.
Potassium-sparing diuretics act mainly in the collecting duct.
Here, sodium reabsorbs through epithelial sodium channels, ENaC, then sodium/potassium
pump, in exchange for potassium loss.
Sodium influx into cells creates a negative lumen potential, which drives reabsorption
of chloride and excretion of potassium and hydrogen.
Both ENaC and sodium/potassium pump are induced by aldosterone.
Potassium-sparing diuretics include aldosterone receptor antagonists and direct ENaC inhibitors.
They are called potassium-sparing because they do not increase potassium loss, unlike
all other diuretics acting upstream.
Instead, they reduce potassium loss because reduced sodium reabsorption decreases the
electrogenic exchange for potassium.
Aldosterone antagonists also directly inhibit the sodium/potassium pump, reducing potassium
loss.
Because the collecting duct reabsorbs only a small amount of sodium, this class of drugs
has only a mild diuretic effect.
They are commonly used in conjunction with thiazide or loop diuretics to prevent hypokalemia.
Side effects include hyperkalemia, metabolic acidosis, and effects associated with inhibition
of aldosterone.